CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex

Molecular Psychiatry

Volumn 19, Issue 5, 2014, Pages 536-543

  Cass, D K ^a   Flores Barrera, E ^a   Thomases, D R ^a   Vital, W F ^a   Caballero, A ^a   Tseng, K Y ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

adolescence; cannabinoid; CB1 receptor; GABA; prefrontal cortex; ventral hippocampus

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; INDIPLON; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BENZOXAZINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; GABRA1 PROTEIN, RAT; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ADOLESCENCE; ADOLESCENT; ADULT; ADULTHOOD; ANIMAL EXPERIMENT; ARTICLE; BRAIN MATURATION; CONTROLLED STUDY; DOWN REGULATION; GABAERGIC TRANSMISSION; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION (PSYCHOLOGY); NERVE POTENTIAL; NERVE STIMULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; AGONISTS; ANIMAL; DRUG EFFECTS; ELECTROSTIMULATION; GROWTH, DEVELOPMENT AND AGING; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; METABOLISM; NERVE CELL; PATCH CLAMP TECHNIQUE; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANIMALS; BENZODIAZEPINES; BENZOXAZINES; CENTRAL NERVOUS SYSTEM AGENTS; ELECTRIC STIMULATION; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; INHIBITORY POSTSYNAPTIC POTENTIALS; MALE; MORPHOLINES; NAPHTHALENES; NEURONS; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; PYRAZOLES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; SYNAPTIC TRANSMISSION; THIOPHENES;

EID: 84899472236     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.14     Document Type: Article

References (48)

1. Andersen SL. Trajectories of brain development: point of vulnerability or windowof opportunity? Neurosci Biobehav Rev 2003; 27: 3-18. (Pubitemid 36535387)
2. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivationin adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003;160: 1041-1052. (Pubitemid 41070962)
3. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge duringadolescence? Nat Rev Neurosci 2008; 9: 947-957.
4. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al.Moderation of the effect of adolescent-onset cannabis use on adult psychosis bya functional polymorphism in the catechol-O-methyltransferase gene: longitudinalevidence of a gene X environment interaction. Biol Psychiatry 2005; 57:1117-1127. (Pubitemid 40615773)
5. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia:the role of cannabis use. Schizophr Bull 2005; 31: 608-612. (Pubitemid 41253312)
6. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al.Cannabis use and risk of psychotic or affective mental health outcomes: asystematic review. Lancet 2007; 370: 319-328. (Pubitemid 47094993)
7. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS et al. Persistentcannabis users show neuropsychological decline from childhood to midlife. ProcNatl Acad Sci USA 2012; 109: E2657-E2664.
8. McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR et al.Association between cannabis use and psychosis-related outcomes usingsibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67:440-447.
9. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatialworking memory in heavy cannabis users: a functional magnetic resonanceimaging study. Psychopharmacology (Berl) 2004; 176: 239-247. (Pubitemid 40012729)
10. Schweinsburg AD, Brown SA, Tapert SF. The influence of marijuana use onneurocognitive functioning in adolescents. Curr Drug Abuse Rev 2008; 1: 99-111.
11. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al. Cognitivefunctioning of long-term heavy cannabis users seeking treatment. Jama 2002;287: 1123-1131. (Pubitemid 34252081)
12. Best JR, Miller PH. A developmental perspective on executive function. Child Dev2010; 81: 1641-1660.
13. Casey BJ, Giedd JN, Thomas KM. Structural and functional brain development andits relation to cognitive development. Biol Psychol 2000; 54: 241-257.
14. O'Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposureproduces lasting memory impairment and increased anxiety in adolescent butnot adult rats. J Psychopharmacol 2004; 18: 502-508. (Pubitemid 39665118)
15. Raver SM, Haughwout SP, Keller A. Adolescent cannabinoid exposure permanentlysuppresses cortical oscillations in adult mice. Neuropsychopharmacology2013; 38: 2338-2347.
16. Renard J, Krebs MO, Jay TM, Le Pen G. Long-term cognitive impairments inducedby chronic cannabinoid exposure during adolescence in rats: a strain comparison.Psychopharmacology (Berl) 2013; 225: 781-790.
17. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoidtreatment impairs sensorimotor gating, recognition memory, and the performancein a progressive ratio task in adult rats. Neuropsychopharmacology 2003;28: 1760-1769. (Pubitemid 41070841)
18. Schneider M, Schomig E, Leweke FM. Acute and chronic cannabinoid treatmentdifferentially affects recognition memory and social behavior in pubertal andadult rats. Addict Biol 2008; 13: 345-357.
19. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture ofnatural cannabinoids. Life Sci 2005; 78: 539-548. (Pubitemid 41653504)
20. Caballero A, Tseng KY. Association of cannabis use during adolescence, prefrontalCB1 receptor signaling, and schizophrenia. Front Pharmacol 2012; 3: 101.
21. Realini N, Rubino T, Parolaro D. Neurobiological alterations at adult agetriggered by adolescent exposure to cannabinoids. Pharmacol Res 2009; 60:132-138.
22. Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disruptssensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry2008; 63: 1075-1083.
23. Uhlhaas PJ, Linden DE, Singer W, Haenschel C, Lindner M, Maurer K et al. Dysfunctionallong-range coordination of neural activity during Gestalt perception inschizophrenia. J Neurosci 2006; 26: 8168-8175. (Pubitemid 44315141)
24. Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitivedysfunctions and pathophysiology. Neuron 2006; 52: 155-168. (Pubitemid 44466360)
25. Caballero A, Flores-Barrera E, Cass DK, Tseng KY. Differential regulation of parvalbuminand calretinin interneurons in the prefrontal cortex during adolescence.Brain Struct Funct 2014; 219: 395-406.
26. Thomases DR, Cass DK, Tseng KY. Periadolescent exposure to the NMDA receptorantagonist MK-801 impairs the functional maturation of local GABAergic circuitsin the adult prefrontal cortex. J Neurosci 2013; 33: 26-34.
27. Cass DK, Thomases DR, Caballero A, Tseng KY. Developmental disruption ofgamma-aminobutyric acid function in the medial prefrontal cortex by noncontingentcocaine exposure during early adolescence. Biol Psychiatry 2013; 74:490-501.
28. Tagliaferro P, Javier Ramos A, Onaivi ES, Evrard SG, Lujilde J, Brusco A. Neuronalcytoskeleton and synaptic densities are altered after a chronic treatment with thecannabinoid receptor agonist WIN 55,212-2. Brain Res 2006; 1085: 163-176.
29. Wegener N, Koch M. Behavioural disturbances and altered Fos protein expressionin adult rats after chronic pubertal cannabinoid treatment. Brain Res 2009; 1253:81-91.
30. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press:New York, 1998.
31. Flores-Barrera E, Thomases DR, Heng LJ, Cass DK, Caballero A, Tseng KY. Lateadolescent expression of GluN2B transmission in the prefrontal cortex is inputspecificand requires postsynaptic PKA and D1 dopamine receptor signaling. BiolPsychiatry 2014; 75: 508-516.
32. Heng LJ, Markham JA, Hu XT, Tseng KY. Concurrent upregulation of postsynapticL-type Ca(2+) channel function and protein kinase A signaling is required for theperiadolescent facilitation of Ca(2+) plateau potentials and dopamine D1 receptormodulation in the prefrontal cortex. Neuropharmacology 2011; 60: 953-962.
33. Becker B, Wagner D, Koester P, Bender K, Kabbasch C, Gouzoulis-Mayfrank E et al.Memory-related hippocampal functioning in ecstasy and amphetamine users: aprospective fMRI study. Psychopharmacology (Berl) 2012; 225: 923-934.
34. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L et al. Specificattentional dysfunction in adults following early start of cannabis use. Psychopharmacology(Berl) 1999; 142: 295-301. (Pubitemid 29200157)
35. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR et al.Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry2011; 198: 442-447.
36. Caballero A, Thomases DR, Flores-Barrera E, Cass DK, Tseng KY. Emergence ofGABAergic-dependent regulation of input-specific plasticity in the adult rat prefrontalcortex during adolescence. Psychopharmacology (Berl) advance onlinepublication, 2 August 2013; doi:10.1007/s00213-013-3216-4 (e-pub ahead ofprint).
37. Heng L, Beverley JA, Steiner H, Tseng KY. Differential developmental trajectoriesfor CB1 cannabinoid receptor expression in limbic/associative and sensorimotorcortical areas. Synapse 2011; 65: 278-286.
38. Tseng KY, O'Donnell P. Post-pubertal emergence of prefrontal cortical up statesinduced by D1-NMDA co-activation. Cereb Cortex 2005; 15: 49-57. (Pubitemid 40019051)
39. Tseng KY, O'Donnell P. Dopamine modulation of prefrontal cortical interneuronschanges during adolescence. Cereb Cortex 2007; 17: 1235-1240. (Pubitemid 46598865)
40. Tseng KY, O'Donnell P. D2 dopamine receptors recruit a GABA component fortheir attenuation of excitatory synaptic transmission in the adult rat prefrontalcortex. Synapse 2007; 61: 843-850. (Pubitemid 47328803)
41. Atakan Z. Cannabis, a complex plant: different compounds and different effectson individuals. Ther Adv Psychopharmacol 2012; 2: 241-254.
42. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plantcannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
43. Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front HumNeurosci 2009; 3: 53.
44. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al. Thepsychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthyindividuals: implications for psychosis. Neuropsychopharmacology 2004; 29:1558-1572. (Pubitemid 38982249)
45. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley Get al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications forcognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608. (Pubitemid 40409699)
46. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids.Psychopharmacology (Berl) 2013; 228: 525-540.
47. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. "Spice" and "K2"herbal highs: a case series and systematic review of the clinical effects andbiopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict2012; 21: 320-326.
48. Lovinger DM, Zimmerman SA, Levitin M, Jones MV, Harrison NL. Trichloroethanolpotentiates synaptic transmission mediated by gamma-aminobutyricacidA receptors in hippocampal neurons. J Pharmacol Exp Ther 1993; 264:1097-1103. (Pubitemid 23318599)